GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (STU:BS50) » Definitions » Long-Term Capital Lease Obligation

Inotiv (STU:BS50) Long-Term Capital Lease Obligation : €34.2 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Inotiv Long-Term Capital Lease Obligation?

Inotiv's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €34.2 Mil.

Inotiv's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 (€27.7 Mil) to Dec. 2023 (€34.9 Mil) but then declined from Dec. 2023 (€34.9 Mil) to Mar. 2024 (€34.2 Mil).

Inotiv's annual Long-Term Capital Lease Obligation increased from Sep. 2021 (€5.6 Mil) to Sep. 2022 (€25.1 Mil) and increased from Sep. 2022 (€25.1 Mil) to Sep. 2023 (€27.7 Mil).


Inotiv Long-Term Capital Lease Obligation Historical Data

The historical data trend for Inotiv's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Long-Term Capital Lease Obligation Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.88 5.57 25.10 27.75

Inotiv Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.57 29.35 27.75 34.91 34.24

Inotiv  (STU:BS50) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Inotiv Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Inotiv's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Inotiv (STU:BS50) Business Description

Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Inotiv (STU:BS50) Headlines

No Headlines